Zydus Lifesciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for the Pre-Approval Inspection (PAI) conducted at SEZ oncology injectable manufacturing site in SEZ1, Ahmedabad, in relation to the new isolator injectable line. The inspection was conducted from 4th to 13th November, 2025

Zydus Lifesciences announced that ESG Risk Assessments and Insights (ESGRAIL), a SEBI registered ESG Rating Provider has assigned overall ESG rating of 68 (last year 66) to the Company.

Zydus Lifesciences Ltd gained for a fifth straight session today. The stock is quoting at Rs 907, up 1.73% on the day as on 12:39 IST on the NSE. The benchmark NIFTY is down around 0.59% on the day, quoting at 23855.35. The Sensex is at 76913.19, down 0.84%. Zydus Lifesciences Ltd has slipped around 1.74% in last one month.

Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has slipped around 4.54% in last one month and is currently quoting at 21991.2, up 0.94% on the day. The volume in the stock stood at 3.71 lakh shares today, compared to the daily average of 6.62 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 908, up 1.63% on the day. Zydus Lifesciences Ltd is up 4.39% in last one year as compared to a 4.5% spurt in NIFTY and a 8.48% spurt in the Nifty Pharma index.

The PE of the stock is 19.1 based on TTM earnings ending December 25.

The drug is the generic version of Farxiga? Tablets, 5 mg and 10 mg. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. The tablets will be manufactured at the group?s formulation facility at SEZ, Ahmedabad.

According to IQVIA MAT February 2026 data, Dapagliflozin tablets had annual sales of $10.2 billion in the United States. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity. The group now has 436 USFDA approvals and has filed 505 ANDAs since it began filing in FY2003-04.

Zydus Lifesciences operates as an integrated pharmaceutical company across research, development, production, marketing, and distribution of pharmaceutical products.

The company?s consolidated net profit rose 7.7% to Rs 1,102.64 crore on a 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.